Evidence map›Paper›PMID 35946042›Full record

ArticleAmerican heart journal plus : cardiology research and practice2022

Clinical outcomes of COVID-19 infection in patients with pre-existing cardiovascular disease.

Mina Medhat Kerolos, Max Ruge, Ahmad Gill, Maria Isabel Planek, Annabelle Santos Volgman, Jeanne M Du-Fay-De-Lavallaz, Joanne Michelle D Gomez, Tisha Marie Suboc, Kim A Williams, Salaheldin Abusin

Open access · goldAbstract read
In one paragraph

Article in American heart journal plus : cardiology research and practice, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Impact of New Onset Atrial Fibrillation in Hospitalized Patients with COVID-19. Results of the "ACO-VID" Registry.Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Mina Medhat KerolosDepartment of Internal Medicine, Rush University Medical Center, Chicago, IL, United States of America.
Max RugeDepartment of Internal Medicine, Thomas Jefferson University Hospitals, Philadelphia, PA, United States of America.
Ahmad GillDepartment of Internal Medicine, University of Nevada, Las Vegas, NV, United States of America.
Maria Isabel PlanekDepartment of Internal Medicine, Rush University Medical Center, Chicago, IL, United States of America.
Annabelle Santos VolgmanDivision of Cardiology, Rush University Medical Center, Chicago, IL, United States of America.
Jeanne M Du-Fay-De-LavallazDepartment of Internal Medicine, Rush University Medical Center, Chicago, IL, United States of America.
Joanne Michelle D GomezDivision of Cardiology, Sharp Memorial Hospital, San Diego, CA.
Tisha Marie SubocDivision of Cardiology, Rush University Medical Center, Chicago, IL, United States of America.
Kim A WilliamsDivision of Cardiology, Rush University Medical Center, Chicago, IL, United States of America.
Salaheldin AbusinDivision of Cardiology, Rush University Medical Center, Chicago, IL, United States of America.
Rush University Medical Center · USSharp Memorial Hospital · USThomas Jefferson University Hospital · USUniversity of Nevada, Las Vegas · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Patients with pre-existing cardiovascular disease may carry a higher risk for mortality from COVID-19. This study examined the association between individuals with pre-existing cardiovascular disease admitted for COVID-19 and their clinical outcomes. Methods: A retrospective cohort study was conducted on patients admitted with COVID-19 to Rush University System for Health (RUSH) to identify cardiovascular risk factors associated with increased mortality and major adverse cardiovascular events (MACE; a composite of cardiovascular death, stroke, myocardial injury, and heart failure exacerbation). Multivariable logistic regression was used to adjust for demographic data and comorbid conditions. Results: Of the 1682 patients who met inclusion criteria, the median age was 59. Patients were predominantly African American (34.4 %) and male (54.5 %). Overall, 202 (12 %) patients suffered 60-day mortality. In the multivariable model that assessed risk factors for 60-day mortality, age 60-74 (adjusted odds ratio [aOR] 3.30 [CI: 1.23-10.62]; p < 0.05) and age 75-100 (aOR 4.52 [CI: 1.46-16.15]; p < 0.05) were significant predictors when compared to those aged 19 to 39. This model also showed that those with past medical histories of atrial fibrillation (aOR 2.47 [CI: 1.38-4.38]; p < 0.01) and venous thromboembolism (aOR 2.00 [CI: 1.12-3.50]; p < 0.05) were at higher risk of 60-day mortality. Conclusion: In this cohort, patients over 60 years old with a pre-existing history of atrial fibrillation and venous thromboembolism were at increased risk of mortality from COVID-19.

Indexed as

60-day outcomesAtrial fibrillationCOVID-19Major adverse cardiovascular eventsVenous thromboembolism

Identifiers

PMID35946042
PMCPMC9354393
OpenAlexW4289938698

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.